Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

117%

7 of 6 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 4

3(37.5%)

Phase 1

1(12.5%)

N/A

1(12.5%)

8Total

Phase 2(3)

Phase 4(3)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04905563Phase 4Terminated

NSAIDs vs Opioids for Post-op Pain in Supracondylar Humerus Fractures

Role: collaborator

NCT01980342Phase 4Terminated

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz

Role: collaborator

NCT02071095Phase 1Completed

Enhancement by Poly-ICLC During HIV-1 Infection

Role: collaborator

NCT00414635Phase 4Completed

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

Role: collaborator

NCT01001767Phase 2Completed

Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease

Role: collaborator

NCT01578772Phase 2Completed

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

Role: collaborator

NCT01093651Phase 2Completed

Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV

Role: collaborator

NCT00025753Not ApplicableCompleted

Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution

Role: collaborator

All 8 trials loaded